Modality
Small Molecule
MOA
KIF18Ai
Target
CD38
Pathway
Incretin
NBFSGSGBM
Development Pipeline
Preclinical
Jun 2019
→ Jun 2031
PreclinicalCurrent
NCT03362083
2,943 pts·NB
2019-06→2031-06·Recruiting
NCT08444500
1,850 pts·GBM
2021-02→2028-10·Not yet recruiting
4,793 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-10-232.6y awayInterim· GBM
2031-06-115.2y awayInterim· NB
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Recruit…
Preclinical
Not yet…
Catalysts
Interim
2028-10-23 · 2.6y away
GBM
Interim
2031-06-11 · 5.2y away
NB
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03362083 | Preclinical | NB | Recruiting | 2943 | UPDRS |
| NCT08444500 | Preclinical | GBM | Not yet recr... | 1850 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 |